GlassScriptPhysician profile
Thomas Mark Mamalakis
NPI 1346810173
$12,149.98
in general payments reported to CMS, 2019-2025
28 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,086 · 2022: $2,414 · 2023: $3,481 · 2024: $2,880 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,485 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,484.71 |
| Education | $165.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,507.62 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,379.62 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,165.94 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,074.68 | 2021-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $730.38 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $718.20 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $683.99 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $650.62 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $526.96 | 2022-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $514.82 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $436.67 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $414.06 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $384.07 | 2021-2024 | Jornay Pm |
| Bausch Health US, LLC | $375.50 | 2021-2025 | Wellbutrin, Aplenzin |
| Neos Therapeutics, LP | $332.31 | 2021-2024 | Adzenys Xr-Odt |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $319.70 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $238.08 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $150.55 | 2022-2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $137.13 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $135.84 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $63.20 | 2022-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $61.37 | 2022 | |
| Noven Therapeutics, LLC | $51.78 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.55 | 2023 | Belsomra |
| Neuronetics, INC. | $27.36 | 2021-2025 | Neurostar Tms Therapy System |
| Eisai INC. | $14.24 | 2021 | |
| Almatica Pharma LLC | $14.16 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mamalakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.